Skip to content
Search

Latest Stories

After Janhvi Kapoor, now Khushi Kapoor is all set to enter Bollywood

After Janhvi Kapoor, now Khushi Kapoor is all set to enter Bollywood

By Murtuza Iqbal

Boney Kapoor and late Sridevi’s daughter, Janhvi Kapoor, made her Bollywood debut with Dhadak in 2018. She then starred in movies like Ghost Stories (Netflix’s anthology) and Gunjan Saxena: The Kargil Girl.


Now, Janhvi’s younger sister, Khushi Kapoor is all set to make Bollywood debut soon. Recently, while talking to Bombay Times, Boney Kapoor opened up about it.

He said, “Yes, Khushi is also keen on acting. You will hear an announcement soon.”

Boney Kapoor himself is a producer, but both his kids, Arjun Kapoor and Janhvi Kapoor were launched by other filmmakers, and Khushi will follow the footsteps of her siblings.

While talking about why he won’t be launching Khushi, the filmmaker said, “I have the resources, but I would rather have someone else launch her because I am her father and one tends to get indulgent. You can’t afford to do that as a filmmaker and nor is it good for the actor. Anil (brother Anil Kapoor) was still an established actor, so it didn’t affect him much, but I think I became an indulgent brother with Sanjay (Sanjay Kapoor) when he made his entry into films.”

He further added, “I would want Khushi to find her own footing. She will be launched by someone I respect and someone I feel secure and safe about.”

Well, we wonder if Khushi will be launched by Karan Johar who had also launched Janhvi Kapoor. Let’s wait and watch.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less